Comment on CMS-2026-1255-0001

Summary: The Cystic Fibrosis Foundation supports the proposed rule to extend electronic prior authorization requirements to prescription drugs, emphasizing the need for transparency and reduced administrative burdens for patients with chronic conditions. They urge CMS to include specific requirements for detailed denial explanations, shorter decision timelines, and protections against alternative funding programs that circumvent standard safeguards.